The brothers RAF.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20141832.
- Also identified by DOI 10.1016/j.cell.2010.01.013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeted molecular therapies for cancer treatment have shown promise, but also have limitations. In this issue, Heidorn et al. (2010) find that a class of targeted molecular therapies with clinical effectiveness against one melanoma subtype may have adverse clinical effects in another.
Medical subject headings
- Melanoma
- Proto-Oncogene Proteins B-raf